9.3 % CAGR of Glioblastoma Market to Gain Around USD 5.99 Billion by 2032 || Report by Emergen Research

The global glioblastoma market has witnessed substantial growth, reaching a size of USD 2.46 Billion in 2022 and is projected to maintain a rapid revenue CAGR of 9.3% during the forecast period. Key drivers of this growth include increased investments in Research & Development (R&D), technological advancements, and rising prevalence of brain cancer.

One of the notable advancements contributing to market growth is the development of novel immunotherapies targeting the tumor microenvironment. These therapies are enabling more personalized and effective treatments for glioblastoma, the most aggressive form of brain cancer.

Moreover, the prevalence of brain cancer, with glioblastoma being the most commonly occurring primary malignant brain tumor, is propelling market expansion. Strategic initiatives by major companies, such as the recent glioblastoma trial launched in Australia, are also expected to drive market revenue.

Download Free Sample Report PDF @ https://www.emergenresearch.com/request-sample/2718

Technological innovations in Next-Generation Sequencing (NGS) and Artificial Intelligence (AI) are further driving market growth. Partnerships like the one between Calyx Medical Imaging and Neosoma aim to advance the development of new glioblastoma treatments through AI-based neuro-oncology software.

Despite these positive trends, the high cost of therapy remains a significant restraint on market revenue growth. However, the dominance of segments like radiation therapy and steady growth in chemotherapy usage indicate promising avenues for market development.

The radiation therapy segment holds the largest market share, driven by advancements in techniques like Intensity-Modulated Radiation Therapy (IMRT) and Stereotactic Radiosurgery (SRS), which improve treatment precision and effectiveness while minimizing damage to healthy brain tissue.

Chemotherapy, another key treatment modality for glioblastoma, is expected to register steady growth due to the prevalence of brain and nervous system cancers. Temozolomide, the most widely used chemotherapeutic agent, has demonstrated consistent efficacy in controlling tumor growth.

In terms of end-use, hospitals dominate the market due to their multidisciplinary approach to glioblastoma treatment. Hospitals provide comprehensive services including surgery, radiation therapy, chemotherapy, and supportive care. Additionally, hospitals offer advanced diagnostic and treatment technologies, ensuring effective care for patients.

Furthermore, hospitals play a crucial role in providing essential supportive care services such as pain management, rehabilitation, and palliative care, driving revenue growth in this segment.

Glioblastoma Top Companies and Competitive Landscape

The global glioblastoma market is fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing a more effective glioblastoma product.

Get Detailed Market Segmentation: https://www.emergenresearch.com/industry-report/glioblastoma-market

Some major players included in the global glioblastoma market report are:
• Novartis AG
• Pfizer Inc.
• GSK
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca
• AbbVie Inc.
• Abbott
• Johnson and Johnson
• Bausch Health Companies Inc.
• Lupin

Glioblastoma Latest Industry Updates

• On 12 October 2022, VBI Vaccines partnered with Agenus to conduct a Phase 2 clinical trial evaluating the effectiveness of combining VBI-1901 for treatment of primary glioblastoma. This decision is to combine VBI-1901 with balstilimab stems from promising data suggesting that VBI-1901 has the potential to activate and boost specific T cells, a type of immune cell capable of targeting and eliminating tumor cells. This collaboration represents a significant step forward in the development of new treatment options for glioblastoma, a disease with a dismal prognosis.

Global glioblastoma market is witnessing significant growth driven by advancements in treatment modalities, technological innovations, and increasing prevalence of brain cancer. While challenges like high therapy costs persist, opportunities for market expansion remain promising, especially with the continued focus on research and development and strategic collaborations within the industry.

Glioblastoma Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global glioblastoma market on the basis of drug class, treatment, end-use, and region:

• Drug Class Outlook (Revenue, USD Billion; 2019-2032)
o Temozolomide
o Bevacizumab
o Lomustine
o Carmustine Wafers
o Others

• Treatment Outlook (Revenue, USD Billion; 2019-2032)
o Chemotherapy
o Radiation Therapy
o Surgical Procedure
o Others

• End-Use Outlook (Revenue, USD Billion; 2019-2032)
o Hospitals
o Clinics
o Ambulatory Surgical Center (ASC)

Request A Customization- https://www.emergenresearch.com/request-for-customization/2718

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. UK
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of Middle East & Africa

For more information and detailed insights, please refer to the latest market research report on the global glioblastoma market.

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.